Strategic partnerships Opportunity: Leverage recent partnership with Spartan Medical to identify cross-sell or integration opportunities with federal government suppliers, healthcare facilities, and distributors that serve government contracts.

Clinical adoption Opportunity: Highlight ongoing leadership in continuous topical oxygen therapy (cTOT) to target wound care clinics, long-term care facilities, and hospital networks seeking proven,袖cost-effective wound healing solutions with clinician-friendly deployment.

Leadership momentum Opportunity: Capitalize on executive appointments (Chairman, VP of U.S. Sales & Global Marketing, CFO) as credibility signals to engage hospital buyers, GPOs, and private equity-backed wound care distributors seeking solid management teams and growth plans.

Financing signal Opportunity: The Series C funding and $49M total funding open doors with investor-backed buyers and strategic partners; approach private equity, venture-backed med-tech buyers, and large distributors looking for scalable, well-capitalized growth stories.

Global exposure Opportunity: Positioned as a Cambridge-based Inotec AMD portfolio company with international R&D and manufacturing alignment; pursue global wound care networks, contract manufacturers, and regional distributors to expand international adoption of NATROX O2.